These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18564326)

  • 1. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives.
    Purohit A; Niederberger V; Kronqvist M; Horak F; Grönneberg R; Suck R; Weber B; Fiebig H; van Hage M; Pauli G; Valenta R; Cromwell O
    Clin Exp Allergy; 2008 Sep; 38(9):1514-25. PubMed ID: 18564326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
    Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
    Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen.
    Larenas-Linnemann D
    Curr Opin Investig Drugs; 2010 May; 11(5):586-96. PubMed ID: 20419605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
    Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
    Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis.
    Pauli G; Larsen TH; Rak S; Horak F; Pastorello E; Valenta R; Purohit A; Arvidsson M; Kavina A; Schroeder JW; Mothes N; Spitzauer S; Montagut A; Galvain S; Melac M; André C; Poulsen LK; Malling HJ
    J Allergy Clin Immunol; 2008 Nov; 122(5):951-60. PubMed ID: 19000581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of Bet v1, Bet v2 and Bet v4 specific IgE antibodies in the sera of children and adult patients allergic to birch pollen: evaluation of different IgE reactivity profiles depending on age and local sensitization.
    Sekerková A; Poláčková M
    Int Arch Allergy Immunol; 2011; 154(4):278-85. PubMed ID: 20962532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allergen immunotherapy for birch pollen-allergic patients: recent advances.
    Moingeon P; Floch VB; Airouche S; Baron-Bodo V; Nony E; Mascarell L
    Immunotherapy; 2016 May; 8(5):555-67. PubMed ID: 27140409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoallergenic derivatives of the major birch pollen allergen Bet v 1 obtained by rational sequence reassembly.
    Campana R; Vrtala S; Maderegger B; Jertschin P; Stegfellner G; Swoboda I; Focke-Tejkl M; Blatt K; Gieras A; Zafred D; Neubauer A; Valent P; Keller W; Spitzauer S; Valenta R
    J Allergy Clin Immunol; 2010 Nov; 126(5):1024-31, 1031.e1-8. PubMed ID: 20638112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular composition and biological activity of commercial birch pollen allergen extracts.
    Focke M; Marth K; Valenta R
    Eur J Clin Invest; 2009 May; 39(5):429-36. PubMed ID: 19302561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination.
    Focke M; Linhart B; Hartl A; Wiedermann U; Sperr WR; Valent P; Thalhamer J; Kraft D; Valenta R
    Clin Exp Allergy; 2004 Oct; 34(10):1525-33. PubMed ID: 15479266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season.
    Kettner A; DellaCorte G; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Simonsen K; Reymond C; Spertini F
    J Allergy Clin Immunol; 2018 Aug; 142(2):678-680.e7. PubMed ID: 29678749
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide.
    Gadermaier E; Flicker S; Aberer W; Egger C; Reider N; Focke M; Vrtala S; Kundi M; Valenta R
    Int Arch Allergy Immunol; 2010; 151(1):17-27. PubMed ID: 19672093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful sublingual immunotherapy with birch pollen has limited effects on concomitant food allergy to apple and the immune response to the Bet v 1 homolog Mal d 1.
    Kinaciyan T; Jahn-Schmid B; Radakovics A; Zwölfer B; Schreiber C; Francis JN; Ebner C; Bohle B
    J Allergy Clin Immunol; 2007 Apr; 119(4):937-43. PubMed ID: 17204315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of birch pollen-specific immunotherapy on birch pollen-related hazelnut allergy.
    van Hoffen E; Peeters KA; van Neerven RJ; van der Tas CW; Zuidmeer L; van Ieperen-van Dijk AG; Bruijnzeel-Koomen CA; Knol EF; van Ree R; Knulst AC
    J Allergy Clin Immunol; 2011 Jan; 127(1):100-1, 101.e1-3. PubMed ID: 20933256
    [No Abstract]   [Full Text] [Related]  

  • 15. Birch pollen-related food allergy: clinical aspects and the role of allergen-specific IgE and IgG4 antibodies.
    Geroldinger-Simic M; Zelniker T; Aberer W; Ebner C; Egger C; Greiderer A; Prem N; Lidholm J; Ballmer-Weber BK; Vieths S; Bohle B
    J Allergy Clin Immunol; 2011 Mar; 127(3):616-22.e1. PubMed ID: 21251701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible induction of oral allergy syndrome during specific immunotherapy in patients sensitive to tree pollen.
    Modrzyński M; Zawisza E
    Med Sci Monit; 2005 Jul; 11(7):CR351-5. PubMed ID: 15990693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy.
    Kahlert H; Suck R; Weber B; Nandy A; Wald M; Keller W; Cromwell O; Fiebig H
    Int Arch Allergy Immunol; 2008; 145(3):193-206. PubMed ID: 17912007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant birch allergens (Bet v 1 and Bet v 2) and the oral allergy syndrome in patients allergic to birch pollen.
    De Amici M; Mosca M; Vignini M; Quaglini S; Moratti R
    Ann Allergy Asthma Immunol; 2003 Nov; 91(5):490-2. PubMed ID: 14692434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study.
    Höiby AS; Strand V; Robinson DS; Sager A; Rak S
    Clin Exp Allergy; 2010 Jul; 40(7):1062-70. PubMed ID: 20642579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of recombinant allergens Bet v 1 and Bet v 2 (profilin) by Pharmacia CAP system in patients with pollen-related allergy to birch and apple.
    Rossi RE; Monasterolo G; Operti D; Corsi M
    Allergy; 1996 Dec; 51(12):940-5. PubMed ID: 9020425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.